A Phase I, Open Label Study to Evaluate the Safety, Pharmacokinetic, Pharmacodynamic and Clinical Activity of PF-06863135, a BCMA-CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Advanced Multiple Myeloma.
Phase of Trial: Phase I
Latest Information Update: 12 Apr 2018
At a glance
- Drugs PF-06863135 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 26 Jan 2018 Planned End Date changed from 6 Dec 2021 to 29 Nov 2021.
- 26 Jan 2018 Planned primary completion date changed from 27 Mar 2021 to 20 Mar 2021.
- 18 Dec 2017 Status changed from not yet recruiting to recruiting.